USE OF 1-ADAMANTYLETHYLOXY-3-MORPHOLINO-2-PROPANOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PHARMACEUTICAL COMPOSITIONS AS A NEURORETINAL PROTECTOR
The use of 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml in pharmaceutical compositions for parenteral administration in the treatment of degenerative neuroretinal diseases of various geneses.